Edgen
Ed'i Ücretsiz Dene
Ryan Patel - Healthcare & Life Sciences Analyst at Edgen

Ryan Patel

Healthcare & Life Sciences Analyst

Drug pipelines, FDA catalysts, and biotech valuation. Came from equity research at Jefferies covering mid-cap pharma. His analysis tends to be contrarian — he'll downgrade a consensus favorite if the Phase 3 data doesn't hold up to scrutiny.
Latest
AbbVie Al olarak derecelendirildi, hedef fiyat $250. FY2025 geliri $61.16B (+%10.6), Skyrizi+Rinvoq $27B yıllık çalışma oranı, FCF $17.8B, Temettü Aristokratı. Tam analiz Edgen'de.

AbbVie Hisse Analizi: Skyrizi ve Rinvoq İlaç Sektörü Tezini Yeniden Tanımlıyor | Edgen

The global pharmaceutical industry in 2026 is navigating a structural transformation driven by three converging forces: the largest patent cliff cycle in the sector's history, the implementation of the Inflation Reduction Act's drug price negotiation provisions, and a widening bifurcation between companies with genuine innovation engines and those reliant on mature, commoditizing portfolios. Between 2023 and 2030, branded drugs representing over $250 billion in peak annual revenue will lose patent protection, exposing companies to biosimilar and generic competition that typically erodes 60-80% of branded revenue within three to five years of exclusivity loss. AbbVie's Humira, which peaked at $21.2 billion in annual sales in 2022 as the world's best-selling drug, was the poster child for this risk. The drug's U.S. biosimilar entry in January 2023 triggered an immediate and sustained revenue decline — Humira revenue fell to approximately $14.4 billion in FY2023, then approximately $10.2
Ryan Patel
·
Apr 20 2026

Yatırım yapmak artık yalnız bir iş değil.

Ed'i ücretsiz dene. Kart yok, taahhüt yok.
Ed'i Ücretsiz Dene